Benchmark Reiterates Hold Rating for Integer (NYSE:ITGR)

Integer (NYSE:ITGR)‘s stock had its “hold” rating reiterated by Benchmark in a note issued to investors on Friday, Marketbeat.com reports.

A number of other research analysts have also weighed in on the stock. Wells Fargo & Company reissued an “equal weight” rating and issued a $80.00 target price (down from $132.00) on shares of Integer in a research note on Friday. Truist Financial lowered their target price on Integer from $137.00 to $121.00 and set a “buy” rating for the company in a research note on Wednesday, October 15th. Wall Street Zen raised Integer from a “hold” rating to a “buy” rating in a research note on Saturday, August 30th. Citigroup cut Integer from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $140.00 to $77.00 in a research note on Thursday. Finally, Raymond James Financial lowered their target price on Integer from $150.00 to $143.00 and set an “outperform” rating for the company in a research note on Friday, July 25th. Four research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $97.75.

Integer Trading Down 1.3%

ITGR opened at $72.94 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 3.71 and a quick ratio of 2.18. The company’s 50 day simple moving average is $103.61 and its two-hundred day simple moving average is $112.48. Integer has a 1-year low of $66.50 and a 1-year high of $146.36. The firm has a market capitalization of $2.56 billion, a price-to-earnings ratio of 30.52, a price-to-earnings-growth ratio of 0.58 and a beta of 0.97.

Integer (NYSE:ITGR) last released its earnings results on Thursday, October 23rd. The medical equipment provider reported $1.79 earnings per share for the quarter, topping analysts’ consensus estimates of $1.68 by $0.11. Integer had a net margin of 4.75% and a return on equity of 12.84%. The business had revenue of $467.69 million for the quarter, compared to analyst estimates of $466.45 million. During the same period last year, the company posted $1.43 EPS. The business’s revenue was up 8.4% on a year-over-year basis. Integer has set its FY 2025 guidance at 6.290-6.430 EPS. Analysts expect that Integer will post 6.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Integer

Institutional investors have recently modified their holdings of the company. Salomon & Ludwin LLC purchased a new stake in shares of Integer during the 3rd quarter worth $26,000. Global Retirement Partners LLC lifted its position in Integer by 293.8% in the third quarter. Global Retirement Partners LLC now owns 319 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 238 shares during the last quarter. Bessemer Group Inc. lifted its position in Integer by 73.1% in the first quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 125 shares during the last quarter. SVB Wealth LLC purchased a new stake in Integer in the first quarter valued at $35,000. Finally, CWM LLC lifted its position in Integer by 46.1% in the second quarter. CWM LLC now owns 355 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 112 shares during the last quarter. 99.29% of the stock is owned by hedge funds and other institutional investors.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.